Anti-MMP-9 Antibody: A Promising Therapeutic Strategy for Treatment of Inflammatory Bowel Disease Complications with Fibrosis

Inflammatory Bowel Diseases

Volumn 22, Issue 9, 2016, Pages 2041-2057

  Goffin, Laurence ^a   Fagagnini, Stefania ^b   Vicari, Alain ^a   Mamie, Céline ^b   Melhem, Hassan ^b   Weder, Bruce ^b   Lutz, Christian ^b   Lang, Silvia ^b   Scharl, Michael ^b   Rogler, Gerhard ^b   Chvatchko, Yolande ^a   Hausmann, Martin ^b  

^a Calypso Biotech SA   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

anti MMP 9 antibody; collagen; fibrosis; mouse; transplantation

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 3; GELATINASE B; HUMAN MONOCLONAL ANTIBODY; HYDROXYPROLINE; MONOCLONAL ANTIBODY AB0046 H4; MONOCLONAL ANTIBODY CALY 001; PROTEIN C3M; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; BIOLOGICAL MARKER; GELATINASE A; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANUS FISTULA; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME DEGRADATION; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HETEROTOPIC TRANSPLANTATION; HUMAN; HUMAN TISSUE; IC50; INTESTINAL FIBROSIS; INTESTINE GRAFT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BLOOD; C57BL MOUSE; CASE CONTROL STUDY; COMPLICATION; DISEASE MODEL; FIBROSIS; GENETICS; INTESTINE; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; PROSPECTIVE STUDY; RECTUM FISTULA; STENOSIS, OCCLUSION AND OBSTRUCTION; SWITZERLAND; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; BIOMARKERS; CASE-CONTROL STUDIES; COLLAGEN TYPE III; CONSTRICTION, PATHOLOGIC; CROHN DISEASE; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; HUMANS; INTESTINAL MUCOSA; INTESTINES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MICE; MICE, INBRED C57BL; MIDDLE AGED; PROSPECTIVE STUDIES; RECTAL FISTULA; SWITZERLAND; YOUNG ADULT;

EID: 84983609916     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000863     Document Type: Article

References (59)

1. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250.
2. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5A-36A.
3. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875-880.
4. Loftus EV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002;16:51-60.
5. Nielsen OH, Rogler G, Hahnloser D, et al. Diagnosis and management of fistulizing Crohn's disease. Nat Clin Pract Gastroenterol Hepatol. 2009; 6:92-106.
6. Agrez M, Gu X, Turton J, et al. The alpha v beta 6 integrin induces gelatinase B secretion in colon cancer cells. Int J Cancer. 1999;81:90-97.
7. Agrez MV, Bates RC, Mitchell D, et al. Multiplicity of fibronectin-binding alpha V integrin receptors in colorectal cancer. Br J Cancer. 1996;73:887-892.
8. Ra H-J, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007;26:587-596.
9. Orlichenko LS, Radisky DC. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis. 2008;25:593-600.
10. Lin C-Y, Tsai P-H, Kandaswami CC, et al. Matrix metalloproteinase-9 cooperates with transcription factor Snail to induce epithelialmesenchymal transition. Cancer Sci. 2011;102:815-827.
11. Tan TK, Zheng G, Hsu T-T, et al. Macrophage matrix metalloproteinase-9 mediates epithelial-mesenchymal transition in vitro in murine renal tubular cells. Am J Pathol. 2010;176:1256-1270.
12. Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology. 1999;117:814-822.
13. Kirkegaard T, Hansen A, Bruun E, et al. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut. 2004;53:701-709.
14. Naito Y, Yoshikawa T. Role of matrix metalloproteinases in inflammatory bowel disease. Mol Aspects Med. 2005;26:379-390.
15. Vandooren J, Van den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol. 2013;48:222-272.
16. Matusiewicz M, Neubauer K, Mierzchala-Pasierb M, et al. Matrix metalloproteinase-9: its interplay with angiogenic factors in inflammatory bowel diseases. Dis Markers. 2014;2014:1-8.
17. Manfredi MA, Zurakowski D, Rufo PA, et al. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1091-1096.
18. Kofla-D1ubacz A, Matusiewicz M, Krzesiek E, et al. Metalloproteinase-3 and-9 as novel markers in the evaluation of ulcerative colitis activity in children. Adv Clin Exp Med. 2014;23:103-110.
19. Silosi I, Boldeanu MV, Mogoanta SS, et al. Matrix metalloproteinases (MMP-3 and MMP-9) implication in the pathogenesis of inflammatory bowel disease (IBD). Rom J Morphol Embryol. 2014;55:1317-1324.
20. de Bruyn M, Machiels K, Vandooren J, et al. Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:339-352.
21. de Bruyn M, Arijs I, De Hertogh G, et al. Serum neutrophil gelatinase B-associated lipocalin and matrix Metalloproteinase-9 complex as a Surrogate marker for mucosal healing in patients with Crohn's disease. J Crohns Colitis. 2015;9:1079-1087.
22. Castaneda FE, Walia B, Vijay-Kumar M, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology. 2005;129:1991-2008.
23. Santana A, Medina C, Paz-Cabrera M-C, et al. Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice. World J Gastroenterol. 2006;12:6464-6472.
24. Liu H, Patel NR, Walter L, et al. Constitutive expression of MMP9 in intestinal epithelium worsens murine acute colitis and is associated with increased levels of proinflammatory cytokine Kc. Am J Physiol Gastrointest Liver Physiol. 2013;304:G793-G803.
25. Meier R, Lutz C, Cosín-Roger J, et al. Decreased fibrogenesis after treatment with pirfenidone in a newly developed mouse model of intestinal fibrosis. Inflamm Bowel Dis. 2016;22:569-582.
26. Pittet V, Juillerat P, Mottet C, et al. Cohort profile: the Swiss inflammatory bowel disease cohort study (SIBDCS). Int J Epidemiol. 2009;38:922-931.
27. Barascuk N, Veidal SS, Larsen L, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neoepitope of type III collagen. Clin Biochem. 2010;43:899-904.
28. Genovese F, Barascuk N, Larsen L, et al. Biglycan fragmentation in pathologies associated with extracellular matrix remodeling by matrix metalloproteinases. Fibrogenesis Tissue Repair. 2013;6:1-10.
29. Leeming D, He Y, Veidal S, et al. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers. 2011;16:616-628.
30. Bay-Jensen AC, Leeming DJ, Kleyer A, et al. Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinasederived collagen species: a cross-sectional study. Rheumatol Int. 2012;32: 3565-3572.
31. Veidal SS, Karsdal MA, Vassiliadis E, et al. MMP mediated degradation of type VI collagen is highly associated with liver fibrosis-identification and validation of a novel biochemical marker assay. PLoS One. 2011;6:e24753.
32. Marshall DC, Lyman SK, McCauley S, et al. Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer. PLoS One. 2015;10:e0127063.
33. Schaefer BC, Schaefer ML, Kappler JW, et al. Observation of antigendependent CD8+ T-cell/dendritic cell interactions in vivo. Cell Immunol. 2001;214:110-122.
34. Medina C, Videla S, Radomski A, et al. Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Am J Physiol Gastrointest Liver Physiol. 2003;284:G116-G122.
35. Ellis AJ, Curry VA, Powell EK, et al. The prevention of collagen breakdown in bovine nasal cartilage by TIMP, TIMP-2 and a low molecular weight synthetic inhibitor. Biochem Biophys Res Commun. 1994;201:94-101.
36. Bergheim I, Guo L, Davis MA, et al. Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J Pharmacol Exp Ther. 2006;316:592-600.
37. Maltz, Schwartz. The role of biologic therapy in the treatment of fistulizing Crohn's disease and maintenance of remission of fistulizing disease. Medscape Gastroenterol. 2007; November.
38. Fidder HH, Singendonk MMJ, van der Have M, et al. Low rates of adherence for tumor necrosis factor-a inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol. 2013; 19:4344-4350.
39. Pedersen G, Saermark T, Kirkegaard T, et al. Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium. Clin Exp Immunol. 2009;155:257-265.
40. Lakatos G, Hritz I, Varga MZ, et al. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases. Dig Dis. 2012;30:289-295.
41. Sandborn WJ, Bhandari BR, Fogel R, et al. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther. 2016;44:157-169.
42. Meijer MJW, Mieremet-Ooms MAC, van der Zon AM, et al. Increased mucosal matrix metalloproteinase-1,-2,-3 and-9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis. 2007;39:733-739.
43. Efsen E, Saermark T, Hansen A, et al. Ramiprilate inhibits functional matrix metalloproteinase activity in Crohn's disease fistulas. Basic Clin Pharmacol Toxicol. 2011;109:208-216.
44. Scharl M, Frei S, Pesch T, et al. Interleukin-13 and transforming growth factor b synergise in the pathogenesis of human intestinal fistulae. Gut. 2013;62:63-72.
45. Bay-Jensen AC, Platt A, Byrjalsen I, et al. Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. Semin Arthritis Rheum. 2014;43:470-478.
46. Mortensen JH, Godskesen LE, Jensen MD, et al. Fragments of citrullinated and MMP-degraded vimentin and MMP-degraded type III collagen are novel serological biomarkers to differentiate Crohn's disease from ulcerative colitis. J Crohns Colitis. 2015;9:863-872.
47. Wiberg C, Hedbom E, Khairullina A, et al. Biglycan and decorin bind close to the n-terminal region of the collagen VI triple helix. J Biol Chem. 2001;276:18947-18952.
48. Högemann B, Edel G, Schwarz K, et al. Expression of biglycan, decorin and proteoglycan-100/CSF-1 in normal and fibrotic human liver. Pathol Res Pract. 1997;193:747-751.
49. Alexander AC, Irving MH. Accumulation and pepsin solubility of collagens in the bowel of patients with Crohn's disease. Dis Colon Rectum. 1990;33:956-962.
50. Rabbani S, Rabbani A, Mohagheghi MA, et al. A novel approach for repairing of intestinal fistula using chitosan hydrogel. J Biomater Appl. 2010;24:545-553.
51. Grgic T, Grgic D, Drmic D, et al. Stable gastric pentadecapeptide BPC 157 heals rat colovesical fistula. Eur J Pharmacol. 2016. doi: 10.1016/j. ejphar.2016.02.038.
52. Volpe BB, da Santos Duarte AS, Ribeiro TB, et al. Mesenchymal stromal cells from adipose tissue attached to suture material enhance the closure of enterocutaneous fistulas in a rat model. Cytotherapy. 2014;16: 1709-1719.
53. Wang X, Zhou Y, Tan R, et al. Mice lacking the matrix metalloproteinase-9 gene reduce renal interstitial fibrosis in obstructive nephropathy. Am J Physiol Physiol. 2010;299:F973-F982.
54. Tan TK, Zheng G, Hsu TT, et al. Matrix metalloproteinase-9 of tubular and macrophage origin contributes to the pathogenesis of renal fibrosis via macrophage recruitment through osteopontin cleavage. Lab Invest. 2013; 93:434-449.
55. Zheng G, Lyons JG, Tan TK, et al. Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-beta1 in renal tubular epithelial cells. Am J Pathol. 2009;175:580-591.
56. Scharl M, Rogler G. Pathophysiology of fistula formation in Crohn's disease. World J Gastrointest Pathophysiol. 2014;5:205-212.
57. Graham MF, Bryson GR, Diegelmann RF. Transforming growth factor beta 1 selectively augments collagen synthesis by human intestinal smooth muscle cells. Gastroenterology. 1990;99:447-453.
58. Barnard JA, Beauchamp RD, Coffey RJ, et al. Regulation of intestinal epithelial cell growth by transforming growth factor type beta. Proc Natl Acad Sci U S A. 1989;86:1578-1582.
59. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000;14:163-176.